The value of tumour marker kinetics in the management of patients with primary hepatocellular carcinoma
โ Scribed by Dr. P. K. Buamah; O. F. W. James; A. W. Skillen; A. L. Harris
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 241 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
Serum alpha-fetoprotein (AFP) has been measured during chemotherapy of ten patients with hepatocellular carcinoma. Whenever the AFP concentration of a sample was lower than that of the previous sample the apparent half-life (AHL) of the protein was calculated. The biological half-life of AFP is 5 days so that values in excess of this were indicative of continuing or increased synthesis and secretion of AFP. The AHL for AFP provided a means of assessing efficacy of treatment. Increases in AHL generally predicted a rise in serum AFP and give advance warning of the need to change therapy.
๐ SIMILAR VOLUMES
## Background: Biochemical markers of bone remodeling have been used as surrogate markers to manage patients with metastatic bone disease. markers of the bone resorptive process, such as the bone collagen breakdown products n-telopeptide and c-telopeptide, are useful markers for monitoring the resp
## Abstract ## BACKGROUND Women with metastatic breast carcinoma have a highly variable clinical course and outcome. Intrinsic genetic heterogeneity of the primary breast tumor may play a role in this variability and may explain it in part. Therefore, the authors tested the hypothesis that the cha